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Renoprotection: Clues from knockout models of rare diseases
Glomerulopathies due to defective known genes are partially or completely reversed at 24 months without
becoming a central source of information in the field clear change in creatinine clearance. Other reports de-
of mechanisms of progression of renal disease. Among scribed no effects of ACE inhibitor in few sporadic cases.
hereditary diseases, Alport syndrome of glomerulopathy In this issue of Kidney International, Gross et al [3]
and hearing loss has long been the best recognized one compared the effects of ramipril given since early stage
and yet the disease remains a major challenge for both versus more advanced disease on renal structure and
basic and clinical scientists. Mutations of the gene encod- function in homozygous 3(IV) chain (COL4A3) knock-
ing for the 5 chain of type IV collagen are the molecular out mice, a model for autosomal-recessive Alport syn-
basis in the classic form, inherited in an X-linked domi- drome. The ACE inhibitor given to mice since 4 weeks
nant pattern (85% of cases). Genetic and phenotypic of life markedly delayed the onset of proteinuria, pro-
heterogeneity, however, is large and other patients have gressive renal damage, and uremia. Remarkably, the
autosomal-recessive or, most rarely, autosomal forms treatment also prolonged their lifespan by several weeks,
resulting from mutations of 3 or 4(IV) collagen chain up to 150 days on average instead of 71 days if continued
genes. The target organs reflect the sites where these until death. Ramipril showed no apparent protective ef-
collagen chains are normally highly expressed and assem- fect against the ultrastrucural changes of the glomerular
bled into functional networks. Thus, the abnormal 5 basement membrane. Conversely, drug treatment ex-
chain appears to prevent incorporation of3 or4 chains erted antifibrotic effects attributable to inhibition of ex-
into the triple helical collagen monomers of the glomeru- cess transforming growth factor  (TGF-) production.
lar membrane. Common to different Alport forms are the ACE inhibitor beginning at 7 weeks of age, when the
typical splitting of the glomerular basement membrane, animals were already heavily proteinuric, had no effect
persistent hematuria, and variable degrees of protein- on renal damage and survival. The main findings in the
uria. End-stage renal failure almost inevitably develops paper by Gross et al [3] that the prolonged treatment
in male patients, as well as in patients with autosomal- with the ACE inhibitor, and, to a lesser extent, a treat-
recessive Alport syndrome in the long term. Despite ad- ment given for a shorter period postponed the onset of
vances in defining the molecular lesion, mechanisms un- uremia and prolonged life revives hopes that patients
derlying the progressive injury in Alport syndrome have with Alport syndrome may have their kidney function
remained obscure. Furthermore, there is no accepted preserved to a significant extent. It was already known
treatment that may delay the time of dialysis or a kidney that the ACE inhibitor could have beneficial effects
transplant. Cyclosporine treatment given for 7 to 10 years against proteinuria, renal function deterioration, and
to eight patients with Alport syndrome (on the theo- survival in Samoyed dogs, a model of X-linked hereditary
retical basis of a favorable hemodynamic action) reduced nephropathy closely mimicking human Alport syndrome
proteinuria and was associated with no aggravation of [4]. However, factor(s) that may be affected by ACE
lesions present at the first biopsy [1]. Angiotensin I-con- inhibitor therapy have remained elusive. In the study by
verting enzyme (ACE) inhibitors have been attempted Gross et al [3], a role for increased glomerular capillary
recently and few preliminary results are published. Pro- pressure could not be formally excluded and the experi-
esmans, Knockaert, and Trouet [2] administered enala- mental protocol lacked a group of mice treated with
pril at a starting dose of 0.1 mg/kg body weight per day other antihypertensive drugs to achieve comparable lev-
to five children with the classical form and two siblings els of blood pressure. Nevertheless, hypertension usually
with the autosomal-recessive form. Overall, proteinuria occurs late and does not seem to play a primary patho-
and protein/creatinine ratio decreased at 6 months and genic role. On the other hand, the reduction of protein-
reached nadirs at 18 months (approximately one fifth uria has been established as an important strategy to
and one tenth from the baseline levels of 40 mg/kg/day retard or prevent the loss of renal function in progressive
and 2.5). This effect, which was observed in five patients, nephropathy. In this respect, the effect of ACE inhibitor
in the COL4A3 knockout mouse, as well as in the dog
model, was no exception. The knockout mice studied byKey words: Alport syndrome, angiotensin-converting enzyme inhibi-
Gross et al uniformly displayed a peculiar onset of dis-tors, proteinuria, glomerular basement membrane, podocyte, trans-
forming growth factor-. ease at 4 weeks and rapid development of severe protein-
uria (5g/L) by 8 weeks eventuating in end-stage renal 2003 by the International Society of Nephrology
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failure. Therefore, it is not surprising that the delayed targets of therapy in progressive nephropathy. For exam-
ACE inhibitor treatment given from 7 weeks, despite ple, in Alport syndrome, where the long-term stability
transient amelioration of the nephrotic syndrome (from of the ultrafiltration barrier is lacking due to defective
6.5g/L to 3.0 g/L) and reduction in TGF- levels (50%) 3-4-5 networks, the ACE inhibitor may initially sta-
by Western blot [3], failed to protect the mice from both bilize the barrier by maintaining slit membrane function,
further worsening of proteinuria and progressive injury. but the inability to normalize the basement membrane
Thus, although factors inherent to the Alport model network, particularly if the network is already severely
might play a role, the continued exposure of the renal compromised, might ultimately account for abnormal
parenchyma to deleterious effects of glomerular barrier permeability of the membrane and long-term failure of
dysfunction, possibly including excess TGF- both prior therapy. Finally, regardless of etiology, angiotensin II is
to and during the delayed treatment, would explain the most likely to play a pivotal role in loss of glomerular
resistance to therapy. permselectivity and progressive renal damage. In iso-
The recent discovery of key molecules of the slit dia- lated rat kidney preparations, the perfusion with angio-
phragm has conclusively led to recognize that the podo- tensin II directly impairs the barrier, resulting in in-
cyte maintains the integrity of the normal glomerular creases in clearance of dextran macromolecular probes
barrier to macromolecules in such a way that inherited and protein excretion rate amenable to abrogation by
abnormalities in podocyte genes may have devastating ACE inhibitor therapy. Excess protein uptake can also
consequences on glomerular and tubular cell biology. be deleterious in itself by promoting TGF- synthesis
Impressively, no studies have been published on path- and podocyte dedifferentiation [8]. The simultaneous
way(s) leading to proteinuria in Alport disease. Thus, inhibition of these pathways may greatly contribute to
putative mechanisms of antiproteinuric action by ACE the beneficial effect of the ACE inhibitor.
were left completely unaddressed. We only know that Gene replacement therapy appears to be a feasible
the ACE inhibitor treatment in the dog model caused prospect for Alport syndrome [9]. In the meantime, alter-
a transient reduction of in the splitting of glomerular native approaches should pursue the goal of preserving
basement membrane [4], whereas ramipril appears to the glomerular barrier. Combining ACE inhibitors and
fail to do so in COL4A3/ mice [3]. The drug is not angiotensin II receptor antagonists may offer a better
expected to affect substantially the inherited molecular therapeutic effect than the treatment with an ACE inhib-
lesion of abnormal collagen network within the glomeru- itor alone. An additional strategy may be aimed at min-
lar basement membrane. In the COL4A3/mice, how- imizing the consequences of permselective barrier dys-
ever, the observation that ramipril preserved the slit function. For example, rats with passive Heymann nephritis
diaphragms and podocyte morphology is a hint that sug- were protected by further combining a statin that may
gests that the podocyte component of the permselective act by inhibition of interstitial fibrogenic reactions [10].
barrier was the primary target of renoprotective therapy. Gross et al point to specific inhibition of TGF-, a target
Such mode of the drug’s action would be in agreement also shown to be effective in other models. In Alport
with findings that the ACE inhibitor prevented glomeru- syndrome, the early detection of patients at risk might
lar redistribution of ZO1 [5] and the reduction in synthe- be needed even before signs of renal disease develop.
sis of nephrin [6] in spontaneous or immune models. We Only well-designed clinical trials can indicate which will
are now also learning from knockout models of genetic be the best way to prevent end-stage renal failure.
glomerulopathies, for example, in Nphs2/ mice defi-
cient for podocin and in a-actinin 4/ mice (abstracts; Mauro Abbate and Giuseppe Remuzzi
Bergamo, ItalyRoselli et al, J Am Soc Nephrol 13:17A, 2002; Kos et al,
J Am Soc Nephrol 13:17A, 2002), that the lack of slit
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